Turn Therapeutics Inc.
TTRXTurn Therapeutics reported deepened GAAP operating losses of -$5.9M amid clinical development investments, partially offset by non-cash gains resulting in net loss of -$3.2M and diluted EPS of -$0.12, with cash burn reflecting ongoing R&D ramp-up.
NASDAQ
Healthcare
Biotechnology
$3.32
+0.20(6.4%)
52W $2.71 – $9.20
Quick:
10-K
Mar 31, 2026 (6 days ago)Annual Report
Full-year financial statements and risk factors
YoY revenue/margin trends, new risk disclosures
8-K
Mar 31, 2026 (6 days ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Mar 24, 2026 (1 weeks ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Feb 17, 2026 (1 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Feb 9, 2026 (1 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Jan 12, 2026 (2 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Jan 7, 2026 (2 months ago)Current Report
Material event disclosure
Event materiality and market reaction
10-Q
Nov 13, 2025 (4 months ago)Quarterly Report
Quarterly financial update
Sequential growth, guidance changes
8-K
Nov 13, 2025 (4 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Nov 12, 2025 (4 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Nov 4, 2025 (5 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Oct 30, 2025 (5 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Oct 28, 2025 (5 months ago)Current Report
Material event disclosure
Event materiality and market reaction
8-K
Oct 22, 2025 (5 months ago)Current Report
Material event disclosure
Event materiality and market reaction
S-1
Oct 9, 2025 (5 months ago)Registration Statement
IPO or secondary offering
Pricing, dilution, use of proceeds
8-K
Oct 2, 2025 (6 months ago)Current Report
Material event disclosure
Event materiality and market reaction
S-1/A
Sep 24, 2025 (6 months ago)Registration Statement (Amendment)
IPO or secondary offering
Pricing, dilution, use of proceeds
S-1/A
Sep 16, 2025 (6 months ago)Registration Statement (Amendment)
IPO or secondary offering
Pricing, dilution, use of proceeds
S-1
Sep 2, 2025 (7 months ago)Registration Statement
IPO or secondary offering
Pricing, dilution, use of proceeds